Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07537400) titled 'Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5' on April 9.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shaare Zedek Medical Center
Condition:
High-Risk Neuroblastoma
Intervention:
Drug: Naxitamab
Recruitment Status: Not recruiting
Phase: Phase 2...